NEW YORK , Aug. 13, 2024 /PRNewswire/ -- The global immunodiagnostics market size is estimated to grow by USD 29.54 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of almost 13.64% during the forecast period. Increased demand for biomarker-based tests is driving market growth, with a trend towards growth in demand for personalized medicine.
However, complexity of immunodiagnostics tests poses a challenge. Key market players include Abbott Laboratories, Adaptive Biotechnologies Corp., AESKU.
GROUP GmbH and Co. KG, bioMerieux SA, Danaher Corp., DiaSorin SpA, Exagen Inc.
, F. Hoffmann La Roche Ltd., HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Nexus Dx Inc.
, Omega Diagnostics Group Plc, OraSure Technologies Inc., QuidelOrtho Corp., Seramun Diagnostica GmbH, Siemens AG, SQI Diagnostics Inc.
, Sysmex Corp., Tecan Trading AG, Thermo Fisher Scientific Inc., and Werfenlife SA.
Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Immunodiagnostics Market Scope Report Coverage Details Base year 2023 Historic period 2018 - 2022 Forecast period 2024-2028 Growth momentum & CAGR Accelerate at a CAGR of 13.64% Market growth 2024-2028 USD 29545.4 million Market structure Fragmented YoY growth 2022-2023 (%) 11.
73 Regional analysis North America, Europe, Asia, and Rest of World (ROW) Performing market contribution Europe at 37% Key countries US, UK, Germany, Canada, and China Ke.